Therapeutic
Area Expertise

Expertise in oncology and inflammatory
disease

Amgen is steeped in the science of creating, producing, and manufacturing life-changing medicines that treat cancer and chronic inflammatory diseases. Throughout our long history in oncology and inflammation, we have brought novel and practice-changing supportive and therapeutic biologics to patients with serious types of cancer and rheumatoid arthritis. We are now applying that experience to developing our biosimilar medicines.

Scientific know-how

We have deep knowledge of the science of creating and producing monoclonal antibodies and fusion proteins, which are more complex than small molecule drugs and some biologic medicines in terms of1:

Size

Structure

Characterization

Stability

Immunogenicity

Manufacturing

Confidence in
efficacy and safety

We believe our global data packages earn complete confidence in our biosimilars. We follow regulatory recommendations to study oncology biosimilars to ensure:

  • The similarity of the biosimilar molecule versus the reference product
  • Safety and effectiveness of biosimilars comparable to that of their reference biologics

Likewise, inflammatory disease specialists can make a confident, evidence-based decision when prescribing an Amgen Biosimilar medicine to their patients with chronic inflammatory diseases.

There for every patient,
every time

Amgen has not had a product shortage in 10 years, ensuring every patient's needs are met, every time. We look forward to continuing this record of quality and reliability with out biosimilars.2

Devices designed for
the disease

Because Amgen is so involved in every aspect of each disease we make medicines for, we are very aware of the challenges patients with these conditions face. And that’s where our committment to device innovation comes in. Enhancing the patient experience with our devices is always our goal, and we have a proven track record of success across therapeutic areas, including oncology and inflammation.

References: 1. Genazzani AA, Biggio G, Caputi AP, et al. BioDrugs. 2007;21:351-356. 2. Data on file, Amgen; 2018.

Next: Biologics Development

previous: Quality Assurance